Merger Monday - AbbVie Acquires Apogee for $10.9B

Apogee Therapeutics (APGE) announced this morning that it has agreed to be acquired by AbbVie (ABBV) in an all-cash transaction at $135.11 per share, representing a roughly 49% premium to the stock's closing price on June 18, 2026, and valuing Apogee at approximately $10.9 billion.

The deal brings together Apogee's diverse pipeline of clinical-stage assets in dermatology, respiratory, and broader inflammatory and immunological diseases, headlined by zumilokibart (APG777), a half-life extended IL-13 monoclonal antibody in late-stage development for atopic dermatitis.

The transaction validates a broader investment thesis in next-generation, half-life extended antibody platforms targeting immunology and inflammatory diseases. Other companies with similar mandates:

Oruka Therapeutics (ORKA), a clinical-stage company developing engineered monoclonal antibody therapeutics for psoriasis and other inflammatory and immunological indications, and Spyre Therapeutics (SYRE), which is pioneering long-acting antibodies and antibody combinations to redefine the standard of care in inflammatory bowel disease and rheumatic diseases. Others include: Damora Therapeutics (DMRA), MoonLake Immunotherapeutics (MLTX), Jade Biosciences (JBIO), Dianthus Therapeutics (DNTH), Viridian Therapeutics (VRDN), Aclaras Therapeutics (ACRS), Upstream Bio (UPB), Immunovant (IMVT), and Eupraxia Pharmaceuticals (EPRX).

Despite having a strong presence in immunology and dermatology via Skyrizi, Rinvoq, and Humira, AbbVie has had a greater focus on Type 1 diseases vs. Type 2, and so Apogee helps fill the Type 2 void. Being Phase 3 ready, AbbVie can control the late-stage development of zumilokibart, suggesting that post-Phase 2/pre-Phase 3 was a good entry point.